Anthem Biosciences Limited (ANTHEM) — Financial Results | 2 July 2026

· NSE Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings

Anthem Biosciences clarified that its FY2026 PAT of ₹5,917.92 million matches the XBRL filing, correcting a prior discrepancy, and will promptly revise the XBRL to include consolidated EPS after an inadvertent clerical omission.

📄 View Original Announcement (PDF)

About Anthem Biosciences Limited (ANTHEM)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹53,084.93 Cr P/E: 91.9 ROE: 18.9% ROCE: 25.5% Div Yield: 0.21%

View full ANTHEM stock details →

📡 Get AI alerts when ANTHEM files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track ANTHEM — Free

📊 More ANTHEM filings

See all ANTHEM filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when ANTHEM files new disclosures

Track ANTHEM filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track ANTHEM — Free

Free account · 2 AI queries/day